EpiVax Oncology To Present Latest Research On The Importance Of Identifying And Removing, Using Machine-Learning Based Advanced Computational Tools, Inhibitory Neoantigens From Therapeutic Cancer Vaccines, At AACR Annual Meeting 2019

EpiVax Oncology To Present Latest Research On The Importance Of Identifying And Removing, Using Machine-Learning Based Advanced Computational Tools, Inhibitory Neoantigens From Therapeutic Cancer Vaccines, At AACR Annual Meeting 2019

THIS ORIGINAL ARTICLE WAS PUBLISHED IN PR NEWSWIRE. LINK TO THE ORIGINAL ARTICLE CAN BE FOUND HERE. NEW YORK, March 25, 2019 /PRNewswire/ — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that its abstract has been selected for...
EpiVax Gives Back in 2018, Looks Forward to 2019!

EpiVax Gives Back in 2018, Looks Forward to 2019!

EpiVax Re-Pledges Commitment to Improving [Human] Health Everywhere Providence, R.I., December 28th, 2018 EpiVax, Inc. is once more pledging to fulfill its mission to “improve human health everywhere”. The employees of this Providence-based, privately-owned...
Leslie J. De Groot MD, 1928-2018

Leslie J. De Groot MD, 1928-2018

              Leslie J. DeGroot MD (“Les”) was born in Fort Edward NY in 1928, dedicated his life to thyroid disease research and endocrinology and died soon after his 90th birthday, on October 23, 2018 in Nonquitt, Massachusetts,...
PANDA: The Newest Product at EpiVax

PANDA: The Newest Product at EpiVax

Revolutionizing Risk Assessment: Generic Peptide Drugs and Their Impurities EpiVax has been awarded a $1 million contract from the Food and Drug Administration (FDA) to demonstrate and validate the best practices and procedures for assessing generic peptide drugs and...
EpiVax Oncology Completes a $1.2M Bridge Financing

EpiVax Oncology Completes a $1.2M Bridge Financing

NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate...